News|Articles|October 7, 2026 (Updated: October 9, 2026)

Intensive BP Control Cuts CV Risk Regardless of CKD Status

A meta-analysis of 27 trials found 15% lower cardiovascular (CV) event risk per 10-mm Hg SBP reduction, with eGFR declines but no rise in kidney failure.

Intensive blood pressure (BP) lowering reduced the risk of major cardiovascular (CV) events by 15% for every 10-mm Hg reduction in systolic BP (SBP) in adults with or without chronic kidney disease (CKD), according to a systematic review and meta-analysis published in JAMA Cardiology. The strategy increased the risk of sustained declines in estimated glomerular filtration rate (eGFR) but did not increase the risk of kidney failure. These findings have direct implications for pharmacists who titrate antihypertensive regimens and monitor kidney function.1

Since 2021, the Kidney Disease: Improving Global Outcomes guidelines have recommended an SBP target of less than 120 mm Hg for individuals with CKD. The study authors note, however, that uncertainty about intensive BP lowering in established CKD, particularly at an eGFR below 30 mL/min/1.73 m², has led to inconsistent targets across guidelines. In practice, pharmacists may see patients with CKD managed to different goals depending on which guideline a clinician follows.1,2

Updated Analysis Adds 3 Large Trials

The investigators identified 27 randomized clinical trials, including 88,830 participants. These included 3 large trials reported since previous CKD-focused meta-analyses: ESPRIT, BPROAD, and STEP. Results were standardized to each trial’s achieved SBP difference.1

CV Benefit Held in Patients With CKD

Overall, intensive BP lowering reduced CV events per 10 mm Hg lower SBP (relative risk [RR], 0.85; 95% CI, 0.81-0.89). Among patients with CKD, the reduction was 11% (RR, 0.89; 95% CI, 0.81-0.99). That was comparable to the 16% reduction in those without CKD (RR, 0.84; 95% CI, 0.80-0.88; P for heterogeneity = .26).1

CV events occurred more often in patients with CKD, so the estimated absolute benefit was at least as large in that group: 4.2 vs 2.7 events avoided per 1000 person-years. That makes patients with CKD a high-yield population for pharmacist-led BP optimization. In an exploratory analysis, intensive BP lowering also reduced all-cause mortality (RR, 0.89; 95% CI, 0.83-0.95).1

Even so, the study's corresponding author cautioned that the findings do not support a single target for every patient. "Decisions to target blood pressure to < 120 mm Hg should be personalized, as it would not be appropriate for all patients with CKD," said Parminder K. Judge, PhD, associate professor at Oxford Population Health and honorary consultant nephrologist at Oxford University Hospitals, in an interview with Pharmacy Times.

eGFR Declines Did Not Translate to Kidney Failure

Intensive BP lowering had no effect on kidney failure (RR, 0.97; 95% CI, 0.84-1.11). The result held when within-trial and post-trial data covering 1331 kidney failure outcomes were combined (RR, 0.93; 95% CI, 0.84-1.02). However, intensive lowering increased the risk of sustained eGFR declines of 30% or greater (RR, 1.42; 95% CI, 1.28-1.58) and 40% or greater (RR, 1.47; 95% CI, 1.30-1.66).1

What Pharmacists Should Watch

Regimen changes drove much of the kidney signal. In the recent large trials, intensive targets were reached with greater use of diuretics and calcium channel blockers. Use of renin-angiotensin system inhibitors differed only modestly between arms. Diuretic use at study end was 43% vs 15% in ESPRIT and 67% vs 43% in SPRINT.1

The authors suggest that the eGFR declines may reflect hemodynamic responses to the added diuretics. They note that smaller percentage declines are less reliable markers of kidney failure when a treatment causes an acute eGFR dip.1,3,4

Judge said monitoring should follow the regimen. "Changes to blood pressure–lowering regimens, particularly when targeting more intensive targets [compared with less intensive targets], should prompt clinicians to monitor blood pressure as well as symptoms that might be related to low blood pressure, such as dizziness or lightheadedness when standing," he said. "Depending on which treatments are used to lower blood pressure, and particularly if diuretics are used to achieve a more intensive target, eGFR and electrolytes should be monitored. Kidney function may drop due to the hemodynamic effect of lowering blood pressure."

That context can help pharmacists interpret an early eGFR drop after a diuretic is added, but the authors caution that a small harm cannot be excluded. SPRINT reported more acute kidney injury adverse events with intensive treatment (4.4% vs 2.6%). The authors advise careful monitoring of BP, eGFR, and electrolytes when implementing an intensive strategy.1,3

Counseling Remains Critical

According to Judge, the size of the drop matters. "An eGFR decline after intensification of blood pressure treatment could be a hemodynamic effect of BP-lowering treatment but could also represent a clinically meaningful decline in kidney function depending on the size of the drop [in percentage terms] from the patient’s usual [or baseline] level of kidney function," he said.

He added that such changes "need not automatically lead to reduction or withdrawal of an antihypertensive regimen but should be interpreted and managed carefully and holistically," taking into account the patient's clinical condition, medical history, and kidney function.

Counseling matters as well, because other analyses have linked intensive BP lowering to hypotension-related adverse events, including syncope and falls. Measurement technique is another consideration. SPRINT used largely unattended standardized measurements, and ESPRIT used clinician-attended standardized office readings. As a result, readings taken at the pharmacy counter may not map directly onto trial targets.1,3,4

REFERENCES
1. Iatridi F, Roddick AJ, Staplin N, et al. Intensive vs standard blood pressure lowering in people with and without chronic kidney disease: a systematic review and meta-analysis. JAMA Cardiol. Published online October 7, 2026. doi:10.1001/jamacardio.2026.4445
2. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2021;99(3S):S1-S87. doi:10.1016/j.kint.2020.11.003
3. SPRINT Research Group; Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103-2116. doi:10.1056/NEJMoa1511939
4. Liu J, Li Y, Ge J, et al; ESPRIT Collaborative Group. Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial. Lancet. 2024;404(10449):245-255. doi:10.1016/S0140-6736(24)01028-6

Related to this article